Publication Name	World Journal of Hepatology
Manuscript ID	18533
Country	Egypt

Received	2015-04-23 08:53
Peer-Review Started	2015-04-24 13:53
To Make the First Decision	2015-07-17 16:30
Return for Revision	2015-07-21 09:25
Revised	2015-08-02 03:10
Second Decision	2015-11-12 14:06
Accepted by Journal Editor-in-Chief	2015-11-12 14:22
Accepted by Executive Editor-in-Chief	2015-11-25 17:16
Articles in Press	2015-11-25 17:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-01 15:19
Publish the Manuscript Online	2015-12-04 15:24

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C genotype 4: The past, present, and future
Manuscript Source	Invited Manuscript
All Author List	Tawhida Y Abdel-Ghaffar, Mostafa M Sira and Suzan El Naghi
Funding Agency and Grant Number
Corresponding Author	Suzan El Naghi, MD, Pediatric Department, National Hepatology and Tropical Medicine Research Institute, 10 - Kasr El Aini Street, Cairo 11441, Egypt. suzan_elnaghi@yahoo.com
Key Words	Hepatitis C virus; Genotypes; Transmission; Pegylated-interferon; Ribavirin; Direct acting antivirals; Hepatitis C virus vaccine
Core Tip	Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% of total global HCV infection. It is higher in limited resource countries. Response rates to a 48-wk peg-interferon/ribavirin combination ranges from 40%-69% for HCV-GT-4. Direct-acting antivirals may significantly improve treatment outcomes in HCV- GT-4, but use of these agents in countries endemic for HCV-GT-4 is currently precluded by the very high costs. A new hepatitis C vaccine from GlaxoSmithKline has shown promise in early clinical tests, prompting strong and broad immune responses. Another Egyptian clinical trial in the field of HCV vaccination: Clinical Trials phases Ⅰ and Ⅱ, started on March 2011. ClinicalTrials.gov Identifier NCT01718834.
Publish Date	2015-12-04 15:24
Citation	Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810
URL	http://www.wjgnet.com/1948-5182/full/v7/i28/2792.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i28.2792

Full Article (PDF)	WJH-7-2792.pdf
Full Article (Word)	WJH-7-2792.doc
Manuscript File	18533-Review.doc
Answering Reviewers	18533-Answering reviewers.pdf
Audio Core Tip	18533-Audio core tip.wav
Conflict-of-Interest Disclosure Form	18533-Conflict-of-interest statement.pdf
Copyright License Agreement	18533-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18533-Language certificate.pdf
Peer-review Report	18533-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	18533-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	18533-Scientific misconduct check.pdf
Scientific Editor Work List	18533-Scientific editor work list.pdf